142 related articles for article (PubMed ID: 37307219)
21. Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.
Tang S; Zhang N; Zhou Y; Cortopassi WA; Jacobson MP; Zhao LJ; Zhong RG
Mol Inform; 2019 Mar; 38(3):e1800089. PubMed ID: 30307134
[TBL] [Abstract][Full Text] [Related]
22. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
23. A structural insight into CK2 inhibition.
Mazzorana M; Pinna LA; Battistutta R
Mol Cell Biochem; 2008 Sep; 316(1-2):57-62. PubMed ID: 18626746
[TBL] [Abstract][Full Text] [Related]
24. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
Chen X; Li C; Wang D; Chen Y; Zhang N
Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
[TBL] [Abstract][Full Text] [Related]
25. A detailed thermodynamic profile of cyclopentyl and isopropyl derivatives binding to CK2 kinase.
Kinoshita T; Sekiguchi Y; Fukada H; Nakaniwa T; Tada T; Nakamura S; Kitaura K; Ohno H; Suzuki Y; Hirasawa A; Nakanishi I; Tsujimoto G
Mol Cell Biochem; 2011 Oct; 356(1-2):97-105. PubMed ID: 21735094
[TBL] [Abstract][Full Text] [Related]
26. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
[TBL] [Abstract][Full Text] [Related]
27. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
Prudent R; Cochet C
Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of new embelin derivatives as CK2 inhibitors.
Oramas-Royo S; Haidar S; Amesty Á; Martín-Acosta P; Feresin G; Tapia A; Aichele D; Jose J; Estévez-Braun A
Bioorg Chem; 2020 Jan; 95():103520. PubMed ID: 31887475
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory Properties of ATP-Competitive Coumestrol and Boldine Are Correlated to Different Modulations of CK2 Flexibility.
Battistutta R; Lolli G
J Nat Prod; 2019 Apr; 82(4):1014-1018. PubMed ID: 30840451
[TBL] [Abstract][Full Text] [Related]
30. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
31. Alternative binding modes of an inhibitor to two different kinases.
De Moliner E; Brown NR; Johnson LN
Eur J Biochem; 2003 Aug; 270(15):3174-81. PubMed ID: 12869192
[TBL] [Abstract][Full Text] [Related]
32. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
[TBL] [Abstract][Full Text] [Related]
33. Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.
Golub AG; Bdzhola VG; Kyshenia YV; Sapelkin VM; Prykhod'ko AO; Kukharenko OP; Ostrynska OV; Yarmoluk SM
Mol Cell Biochem; 2011 Oct; 356(1-2):107-15. PubMed ID: 21735097
[TBL] [Abstract][Full Text] [Related]
34. A novel class of selective CK2 inhibitors targeting its open hinge conformation.
Dalle Vedove A; Zonta F; Zanforlin E; Demitri N; Ribaudo G; Cazzanelli G; Ongaro A; Sarno S; Zagotto G; Battistutta R; Ruzzene M; Lolli G
Eur J Med Chem; 2020 Jun; 195():112267. PubMed ID: 32283296
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase CK2: a newcomer in the 'druggable kinome'.
Pagano MA; Cesaro L; Meggio F; Pinna LA
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1303-6. PubMed ID: 17073807
[TBL] [Abstract][Full Text] [Related]
36. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
[TBL] [Abstract][Full Text] [Related]
37. Development of a potent and selective chemical probe for the pleiotropic kinase CK2.
Wells CI; Drewry DH; Pickett JE; Tjaden A; Krämer A; Müller S; Gyenis L; Menyhart D; Litchfield DW; Knapp S; Axtman AD
Cell Chem Biol; 2021 Apr; 28(4):546-558.e10. PubMed ID: 33484635
[TBL] [Abstract][Full Text] [Related]
38. Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.
Sekiguchi Y; Nakaniwa T; Kinoshita T; Nakanishi I; Kitaura K; Hirasawa A; Tsujimoto G; Tada T
Bioorg Med Chem Lett; 2009 Jun; 19(11):2920-3. PubMed ID: 19414254
[TBL] [Abstract][Full Text] [Related]
39. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.
Hung MS; Xu Z; Lin YC; Mao JH; Yang CT; Chang PJ; Jablons DM; You L
BMC Cancer; 2009 May; 9():135. PubMed ID: 19419583
[TBL] [Abstract][Full Text] [Related]
40. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2').
Sarno S; Reddy H; Meggio F; Ruzzene M; Davies SP; Donella-Deana A; Shugar D; Pinna LA
FEBS Lett; 2001 May; 496(1):44-8. PubMed ID: 11343704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
